HALO: Halozyme Therapeutics Inc. Stocks News on May 10, 2025

HALO

MT Newswires

2 days ago

William O'Neil Initiates Halozyme Therapeutics at Buy

HALO

Simply Wall St.

2 days ago

Halozyme Therapeutics First Quarter 2025 Earnings: Beats Expectations

HALO

Insider Monkey

2 days ago

Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday

HALO

Zacks

2 days ago

HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View

HALO

MT Newswires

3 days ago

Morgan Stanley Raises Price Target on Halozyme Therapeutics to $73 From $67, Keeps Overweight Rating

HALO

GuruFocus.com

3 days ago

Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

HALO

Argus Research

3 days ago

HALO: Lowering target price to $65.00

HALO

Zacks

3 days ago

Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

HALO

Zacks

3 days ago

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

HALO

MT Newswires

3 days ago

Halozyme Therapeutics Q1 Adjusted EPS, Revenue Increase, Boosts 2025 Outlook; Shares Rise

HALO

PR Newswire

3 days ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

HALO

PR Newswire

4 days ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

HALO

Zacks

10 days ago

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

High Growth Tech Stocks in the US Market

HALO

Simply Wall St.

10 days ago

High Growth Tech Stocks in the US Market

HALO

Zacks

11 days ago

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

HALO

MT Newswires

11 days ago

Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation

HALO

PR Newswire

12 days ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

HALO

PR Newswire

12 days ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

HALO

BioPharma Dive

15 days ago

Halozyme sues Merck; FDA blames cuts for Vanda delay

HALO

MT Newswires

15 days ago

Sector Update: Health Care

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

HALO

Zacks

16 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

HALO

MT Newswires

16 days ago

Halozyme Therapeutics Sues Merck for Alleged Patent Infringement

HALO

PR Newswire

16 days ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

HALO

Simply Wall St.

24 days ago

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity

HALO

Argus Research

24 days ago

HALO: Raising target price to $67.00

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

HALO

Investor's Business Daily

a month ago

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

HALO

MT Newswires

a month ago

Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx

HALO

PR Newswire

a month ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

HALO

MT Newswires

a month ago

Halozyme Says European Commission Approves Darzalex Co-Formulated With Enhanze to Treat Multiple Myeloma

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

HALO

PR Newswire

a month ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

HALO

Argus Research

a month ago

HALO: Rating increased to a BUY

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

HALO

Zacks

a month ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

HALO

MT Newswires

a month ago

Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

HALO

PR Newswire

a month ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

HALO

Argus Research

a month ago

HALO: Lowering target price to $65.00

HALO

PR Newswire

a month ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

HALO

Zacks

a month ago

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

HALO

Zacks

a month ago

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

HALO

Argus Research

a month ago

HALO: Raising target price to $68.00

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

HALO

Zacks

2 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

HALO

Zacks

2 months ago

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

HALO

FX Empire

2 months ago

Halozyme Joins the $1 Billion Club

HALO

Investor's Business Daily

2 months ago

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?

HALO

Zacks

2 months ago

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?

HALO

Zacks

2 months ago

HALO vs. AMGN: Which Stock Is the Better Value Option?

HALO

Insider Monkey

2 months ago

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why

AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.

HALO

Barrons.com

2 months ago

AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.

High Growth Tech Stocks To Watch In US March 2025

HALO

Simply Wall St.

2 months ago

High Growth Tech Stocks To Watch In US March 2025

HALO

MT Newswires

2 months ago

Update: Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

HALO

The Wall Street Journal

2 months ago

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

HALO

Zacks

2 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

HALO

MT Newswires

2 months ago

Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version

HALO

Argus Research

2 months ago

HALO: What does Argus have to say about HALO?

HALO

MT Newswires

2 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,260,681, According to a Recent SEC Filing

HALO

PR Newswire

2 months ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

HALO

Argus Research

2 months ago

HALO: What does Argus have to say about HALO?

HALO

Zacks

3 months ago

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

HALO

Zacks

3 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

HALO

Simply Wall St.

3 months ago

Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations

HALO

Zacks

3 months ago

HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth

HALO

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Halozyme Therapeutics Inc Earnings Call

HALO

GuruFocus.com

3 months ago

Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ...

HALO

Argus Research

3 months ago

HALO: Raising target price to $61.00

HALO

Zacks

3 months ago

Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say

HALO

Zacks

3 months ago

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates

HALO

Associated Press Finance

3 months ago

Halozyme Therapeutics: Q4 Earnings Snapshot

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

HALO

Investor's Business Daily

3 months ago

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Q4 Non-GAAP EPS, Revenue Increase

Incyte Stock Sees Relative Strength Rating Rise To 71

HALO

Investor's Business Daily

3 months ago

Incyte Stock Sees Relative Strength Rating Rise To 71

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

HALO

Zacks

3 months ago

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

HALO

Zacks

3 months ago

HALO Gears Up to Report Q4 Earnings: Here's What You Should Know

HALO

Zacks

3 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

HALO

Zacks

3 months ago

Here's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade Ago

HALO

Insider Monkey

3 months ago

Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now

HALO

Investor's Business Daily

3 months ago

Halozyme Stock Climbs Back After 2024 Sneak Peek As Earnings Loom

HALO

Argus Research

3 months ago

HALO: Raising target price to $60.00

HALO

PR Newswire

3 months ago

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Says Non-Small Cell Lung Cancer Treatment Gets Positive Opinion in Europe

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

HALO

PR Newswire

3 months ago

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

HALO

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

High Growth Tech Stocks To Watch In January 2025

HALO

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In January 2025

HALO

Argus Research

3 months ago

HALO: What does Argus have to say about HALO?

HALO

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

HALO

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

HALO

Zacks

3 months ago

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

HALO

Argus Research

4 months ago

HALO: Raising target price to $59.00

BeiGene Stock Meets 80-Plus RS Rating Benchmark

HALO

Investor's Business Daily

4 months ago

BeiGene Stock Meets 80-Plus RS Rating Benchmark

HALO

Zacks

4 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

HALO

Zacks

4 months ago

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

HALO

Argus Research

4 months ago

HALO: Raising target price to $57.00

BridgeBio Pharma Stock Earns 87 RS Rating

HALO

Investor's Business Daily

4 months ago

BridgeBio Pharma Stock Earns 87 RS Rating

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

HALO

Zacks

4 months ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

HALO

Zacks

4 months ago

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

HALO

Zacks

4 months ago

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

HALO

Zacks

4 months ago

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

HALO

Zacks

4 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

HALO

Zacks

4 months ago

HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up

HALO

Zacks

4 months ago

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?

HALO

Zacks

4 months ago

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

SpringWorks Therapeutics Stock Gets A RS Rating Lift

HALO

Investor's Business Daily

4 months ago

Latest Halozyme Therapeutics Inc. (HALO) News on May 10, 2025

Share on Social Networks: